Changes in cell morphology are linked to many cellular events including cytokinesis, differentiation, migration and apoptosis. We recently showed that BNIP-Sa induced cell rounding that leads to apoptosis via its BNIP-2 and Cdc42GAP Homology (BCH) domain, but the underlying mechanism has not been determined. Here, we have identified a unique region (amino acid 133-177) of the BNIP-Sa BCH domain that targets RhoA, but not Cdc42 or Rac1 and only the dominant-negative form of RhoA could prevent the resultant cell rounding and apoptotic effect. The RhoA-binding region consists of two parts; one region (residues 133-147) that shows some homology to part of the RhoA switch I region and an adjacent sequence (residues 148-177) that resembles the REM class I RhoAbinding motif. The sequence 133-147 is also necessary for its heterophilic interaction with the BCH domain of the Rho GTPase-activating protein, p50RhoGAP/ Cdc42GAP. These overlapping motifs allow tripartite competition such that overexpression of BNIP-Sa could reduce p50RhoGAP binding to RhoA and restore RhoA activation. Furthermore, BNIP-Sa mutants lacking the RhoA-binding motif completely failed to induce cell rounding and apoptosis. Therefore, via unique binding motifs within its BCH domain, BNIP-Sa could interact and activate RhoA while preventing its inhibition by p50RhoGAP. This concerted mechanism could allow effective propagation of the RhoA pathway for cell rounding and apoptosis.
Introduction
Apoptosis is a form of cell suicide that plays important roles during embryonic development, wound repair, tissue homeostasis, and the resolution of inflammation; all of which lead to removal of redundant, unhealthy or excess cells (Coleman and Olson, 2002) . Deregulation in this process would therefore result in undesirable outcomes such as tumor formation and organ defects. Apoptosis is triggered by a number of specialist proteins that have evolved to facilitate the process of cell death. The perturbation of normal homeostatic signaling sets off an orchestrated chain of enzymatic activities that lead to the modification of cytoskeletal and signaling proteins and ultimately result in irreversible changes in cell morphology and within the plasma membrane (Kaufmann and Hengartner, 2001; Lockshin and Zakeri, 2004; Gourlay and Ayscough, 2005) .
Cytoskeletal reorganization and degradation has been viewed traditionally as occurring during the later stages of apoptotic death. However, there is increasing evidence showing that the perturbation/disruption of the actin cytoskeleton and microtubule network can initiate apoptotic events. Loss of actin-based, integrinmediated cell-matrix adhesion results in apoptosis (Frisch and Screaton, 2001 ) and direct disruption of the actin cytoskeleton/microtubule network induces apoptosis by modulating various signaling pathways including the Bcl-2 pathway (Korichneva and Hammerling, 1999) , the caspase pathway (White et al., 2001) , the Akt pathway (Flusberg et al., 2001) , and the RhoA/ RhoA-kinase pathway (Song et al., 2002; Bayless and Davis, 2004) . Furthermore, the cytoskeletal network has been shown to modulate apoptosis either positively or negatively in different cell types (Huot et al., 1998; Korichneva and Hammerling, 1999; Posey and Bierer, 1999) . For example, it was found that disruption of the actin cytoskeleton causes apoptosis in T cells (Suria et al., 1999) but it inhibits apoptosis in B lymphocytes (Melamed and Gelfand, 1999) , lymphoma cells (Bando et al., 2002) and articular chondrocytes (Kim et al., 2003) . Furthermore, regulators of actin filaments such as cofilin (Chua et al., 2003) and myosin light chain (Croft et al., 2005) have been implicated in the early phase of apoptosis and apoptotic nuclear disintegration, respectively.
The Rho family small GTPases are major regulators of cell morphology acting on the actin-myosin cytoskeleton where they can also directly influence gene transcription and cell cycle control (Aspenstro¨m, 1999; Ridley, 2001; Sahai and Marshall, 2002; Moon and Zheng, 2003; Collard, 2004) . As major cytoskeleton regulators, the question arises as to what the connections are between the morphological features produced by Rho GTPases and the susceptibility of the cell to apoptosis. Additionally, can Rho induce apoptotic signals leading to cell shape changes and are these two processes coupled, either directly or indirectly? Currently, there are opposing views on the direct role of Rho GTPases in apoptosis, which may reflect the complexity of the process and the interpretation of experimental data (Frisch and Screaton, 2001) . RhoA has been shown, along with Cdc42 and Rac1, to be involved in the rapid apoptotic processes induced by cytotoxic T lymphocytes and Fas via control of the actin cytoskeleton (Subauste et al., 2000) . Rho family GTPases also play important roles in modulating the engulfment of dead cells, a process that intimately involves the cytoskeletal network (Tosello-Trampont et al., 2003) . The characterization of the role of Rho GTPases augmenting apoptosis via an effect on the actin cytoskeleton is an essential element to better understand this important cellular process.
We have recently identified a family of proteins that resemble the prototypical BNIP-2 protein that was first isolated by Boyd et al. (1994) as a binding partner of BCL-2 and the adenovirus E1B 19 kDa protein. We have shown that these related proteins share a conserved domain with p50RhoGAP/Cdc42GAP, which we termed the BNIP-2 and Cdc42GAP Homology (BCH) domain. Proteins containing the BCH domain could form both homophilic and heterophilic associations (Low et al., 2000a, b; Shang et al., 2003) , as well as targeting certain Rho GTPases to elicit distinct cellular effects. For example, the BCH domain of BNIP-2 also binds Cdc42 (Low et al., 2000a, b) and induces cell elongation and membrane protrusions by engaging Cdc42 (Zhou et al., 2005) whereas the BCH domain of BPGAP1, which is closely related to p50RhoGAP, collaborates with both its RhoGAP domain and the proline-rich region to trigger cell protrusions, which are necessary for enhanced cell migration (Shang et al., 2003; Lua and Low, 2004) . We recently identified a novel member for the BNIP-2 family, BNIP-Sa (for BNIP-2 similar splicing isoform-a) which through its BCH domain, exerts a very potent cell rounding effect that follows an initial phase of enhanced cell protrusions, that ultimately leads to apoptosis via a caspaseindependent manner (Zhou et al., 2002) . Furthermore, it was found that one of the splicing variants of BNIP-Sa, BNIPL2, could also induce BCH domain-dependent apoptosis in BEL-7402 cells (Qin et al., 2003) . Although our previous studies have revealed an important role for the homophilic association of BNIP-Sa in apoptosis, the underlying molecular mechanism has not been fully determined. It is noteworthy that the apoptotic process induced by BNIP-Sa could not be prevented by the expression of the antiapoptotic Bcl-2 protein (Zhou et al., 2002) . Since the BCH domain of BNIP-2 utilizes a unique binding motif for targeting Cdc42 in promoting cell protrusions (Zhou et al., 2005) , we hypothesized that other BCH domain-containing members including BNIP-Sa could employ a similar strategy to target specific GTPases via their BCH domains in order to elicit the observed effects on cytoskeletal-controlled cell shape changes.
To test this hypothesis, we set out to examine the effects of BNIP-Sa in regulating the rounding of adherent epithelial cells, followed by mapping the specific regions/domains responsible for binding Rho GTPases and its heterophilic partner, p50Rho-GAP. We demonstrated that the BCH domain of BNIPSa specifically targets RhoA (but not Cdc42 or Rac1) as well as its cognate inactivator, p50RhoGAP. We herein provide evidence whereby BNIP-Sa induces its effects on cell rounding and apoptosis by excluding the interaction of RhoA with its cognate regulator, p50RhoGAP as well as concurrently augmenting the activation of the GTPase. These effects are directed by overlapping motifs within the BCH domain of BNIPSa and binding of the partners occurs on separate molecules of BNIP-Sa. This two-step process could provide a concerted mechanism whereby active RhoA is unhindered to promote cell rounding and subsequent apoptosis.
Results

Morphological and cytoskeletal changes during BNIP-Sa-induced cell rounding and apoptosis
We recently identified that BNIP-Sa induces drastic cell rounding prior to apoptosis and this process is mediated via its BCH domain (Zhou et al., 2002) . To further investigate the possible mechanism underlying this effect, we first examined the effect of BNIP-Sa on the morphological and cytoskeletal changes by determining its disposition with respect to actin filaments and microtubules, as revealed by phalloidin and antitubulin staining, respectively. MCF-7 cells were transfected with green-fluorescent protein (GFP)-BNIP-Sa and monitored for cell shape changes and cytoskeleton network reorganization at 4-h intervals over a period of 20 h (Figure 1a) . At the earlier time points (8-12 h posttransfection), cells expressing BNIP-Sa exhibited an extensive array of short protrusions and thinning in regions where the protein was apparently most abundantly localized, with both actin filaments and the microtubule network remaining intact. During this period of time, BNIP-Sa appeared as punctate spots along the microtubules while that at the cell periphery localized adjacent to the cortical actin. BNIP-Sa also concentrated at the ends of the cell protrusions. Thereafter, most cells started to retract their protrusions and form smaller beads-like cell bodies accompanied by severing of actin filaments as well as disruption of the microtubule network, ultimately leading to massive cell rounding and nuclear condensation, one of the common features of cells undergoing apoptosis (Figure 1b) . Subsequently, these previously adherent cells would detach from the dish as dead cells (data not shown). This data indicated that there was a major cytoskeletal rearrangement associated with BNIP-Sa-induced cell rounding and apoptosis and this prompted us to further examine the potential involvement of Rho small GTPases during this process.
BNIP-Sa specifically interacts with RhoA
We have previously shown that various BCH domains could interact with small GTPases. For example, BNIP-2 binds Cdc42 both in vitro and in vivo via its BCH domain (Zhou et al., 2005) , likewise the BCH domain of BPGAP1 could also interact with Cdc42 (Shang et al., 2003) . These results lead to our hypothesis that different BCH domain-containing proteins could regulate distinct aspects of cell dynamics by targeting small GTPases and we asked the question whether BNIP-Sa had a similar or different binding profile. To this end, we carried out Co-stained with Hoechst dye Figure 1 BNIP-Sa induces cytoskeleton rearrangement during cell rounding and apoptosis. (a) MCF-7 cells were transfected with GFP expression plasmid for the full-length BNIP-Sa. Cells were then fixed after 8, 12, 16 and 20 h and subjected to confocal fluorescence microscopy as described in 'Materials and methods'. Morphological changes and cytoskeletal rearrangements were revealed by direct costaining with rhodamine-conjugated phalloidin for actin filaments or indirect immunostaining with Texas redconjugated goat anti-rabbit IgG against antitubulin for microtubules. BNIP-Sa was directly detected by green fluorescence. Bar, 20 mm. (b) To stain for chromatin integrity, cells transfected with 2 mg of vector or expression constructs of BNIP-Sa were incubated for 10 min with 10 mg/ml of Hoechst dye after 8, 12, 16 and 20 h, washed with phosphate-buffered saline, and examined by microscopy. Cells expressing GFP-BNIP-Sa are marked by arrows, and those that underwent apoptosis (red arrows) exhibited an irregular pattern of staining with Hoechst dye compared with the homogenous staining in live cells.
protein-protein interaction assays to examine whether BNIP-Sa could interact with either RhoA, Cdc42 or/and Rac1 both in vitro and in vivo. Nucleotide-free GSTfusion proteins of RhoA, Cdc42 and Rac1 were prepared and used to interact with BNIP-Sa expressed as a FLAG-tagged protein in 293T cells. Figure 2a shows that only the GST-fusion protein of RhoA, and not Cdc42 nor Rac1, interacted with FLAG-tagged BNIP-Sa. To confirm that lack of BNIP-Sa binding to Cdc42 was not due to the absence of guanine nucleotide in the GST fusions or its different conformations, lysates expressing constituve active (G12V), dominant negative (T17N) or the wild-type form of Cdc42 were subjected to pulldown with GST-BNIP-Sa or GST-BNIP-2 (Figure 2b ). In strong contrast to BNIP-2's preferred binding to Cdc42 T17N that we previously reported (Low et al., 2000b) , BNIP-Sa did not interact with Cdc42 expressed in vivo. To further verify the interaction of BNIP-Sa and RhoA in vivo, FLAGtagged BNIP-Sa and HA-tagged RhoA, Cdc42 or Rac1 were coexpressed in 293T cells followed by immunoprecipitation with anti-FLAG followed by anti-HA to verify the binding partners. Consistent with the GST 'pulldown,' only RhoA was found to interact with BNIP-Sa (Figure 2c ). To exclude the possibility of nonspecific interaction due to dual overexpression, cells expressing only the FLAG-tagged BNIP-Sa was subjected to immunoprecipitation and probed for the endogenous RhoA. It was evident that the endogenous RhoA could also interact with BNIP-Sa (Figure 2d ).
RhoA activity is critical for BNIP-Sa-induced cell rounding We previously showed that the dynamic effects of BNIP-Sa were observed in two stages. Cells transfected with BNIP-Sa initially presented an early phase of membrane protrusions followed by a drastic retraction of these protrusions and subsequent cell rounding that ends in apoptosis (Zhou et al., 2002) . Recently, additional evidence has indicated that Rho GTPases are involved in apoptosis (Bobak et al., 1997; Fiorentini et al., 1998a, b; Mills et al., 1999; Subauste et al., 2000; Dubreuil et al., 2003; Bayless and Davis, 2004) . Since BNIP-Sa specifically interacts with RhoA, we reasoned that RhoA activity could be required for BNIP-Sa to induce cell rounding that leads to apoptosis. This hypothesis was tested by first examining the involvement of Rho pathways in the observed cell responses by expressing the dominant negative or constitutively active forms of HA-tagged RhoA or Cdc42, or the vector alone as a necessary control. These mutants were coexpressed with GFP-tagged BNIP-Sa in the human breast epithelial MCF-7 cells followed by immunostaining and confocal microscopy, as described in 'Materials and methods'. Figure 3 shows that BNIP-Sa-mediated cell rounding could be completely abolished by the dominant-negative RhoA (T19N) and these cells notably also retained the ability to elongate. In comparison, the dominant-negative form of Cdc42 (T17N), constitutively active mutants of RhoA (G14V) or the vector control (data not shown) failed to exert any inhibitory effects on the process of cell rounding. These results demonstrate that an active RhoA pathway is necessary for the cell rounding induced by BNIP-Sa.
The BCH domain of BNIP-Sa mediates its interaction with RhoA Next, we examined which part of BNIP-Sa mediates the interaction with RhoA, and whether such interaction was indeed necessary to elicit its cellular effects. The FLAG-tagged full-length BNIP-Sa or its two deletion mutants, with or without the BCH domain ( Figure 4a) were expressed in 293T cells and used for in vivo coimmunoprecipitation assays with HA-tagged RhoA ( Figure 4b ). The results show that RhoA interacted only with the wild type and CBCH fragment that harbored the BCH domain, but not with the N fragment that lacked this domain. This data indicates that the BCH domain of BNIP-Sa is necessary for specifically targeting RhoA in vivo. To examine further how the conformational changes associated with the nucleotidebinding status of the RhoA could influence their interaction, GST-RhoA fusions were preloaded with GDP or the non-hydrolyzable analog of GTP and used to pulldown FLAG-tagged CBCH fragment of BNIPSa. Figure 4b shows that the GDP-bound form of RhoA exhibited greater binding compared to the unbound RhoA, but the GTP-bound form of RhoA failed to show any interaction. Likewise, when cell lysates expressing constitutive active (G14V), dominant negative (T19N) or the wild-type form of RhoA were subjected to pulldown using the GST-BNIP-Sa, greater amount of RhoA-T19N compared to the wild-type RhoA was precipitated down. However, the constitutive active RhoA-G14V did not show any interaction ( Figure 4c ). These results suggest that BNIP-Sa binding to RhoA is favored when RhoA is in its inactive state. It is also noteworthy that the BCH domain of BNIP-Sa specifically targets RhoA whereas the BCH domains of BNIP-2 and BPGAP1 both target Cdc42, and this could account for the different effects exerted by BNIP-Sa on the changes in cell morphology and later physiological consequences.
Identifying the unique RhoA-binding motif within the BCH domain of BNIP-Sa Since BNIP-Sa targets RhoA with its BCH domain and that active RhoA is necessary for its cell rounding and apoptotic effects, we went on to investigate if this effect was directly linked to their functional interaction. First, the exact RhoA-binding region within the BNIP-Sa BCH domain was to be determined, followed by the application of an appropriately derived non-binding mutant of BNIP-Sa in order to interrogate the significance of their interaction during the morphological changes that leads to apoptosis.
To help identify the possible binding sites, analysis of primary sequences of various Rho-binding proteins and their Rho-binding domains (RBDs) was carried out by comparing them with the BNIP-Sa BCH domain. This analysis revealed a putative 'RBD' at positions 148 to 177 of BNIP-Sa (see Figure 6a ). To verify this, a deletion mutant lacking a segment containing this putative 'RBD' motif (133-177, DA, or extended 'RBD' -ext-RBD) were generated ( Figure 4d ). For controls, another construct lacking a neighboring region (DB, lacking 178-229) which includes the previously identified key binding site (S region, 215-221) for its homophilic interaction (Zhou et al., 2002) was prepared. Both mutants were expressed as FLAG-tagged proteins in 293T cells and subjected to GST 'pulldown' studies. Figure 4e shows that GST-RhoA interacted only with the wild type and DB, but not with the DA/ext-RBD fragment. To verify the integrity of the FLAG-tagged DA/ext-RBD mutant, similar 'pulldown' assays were conducted in parallel experiments using GST-BNIP-Sa. Consistent to our previous report, the DB mutant without the homophilic-interacting motif could not be precipitated by GST-BNIP-Sa whereas the DA/ext-RBD mutant still retained its ability to interact with the wildtype BNIP-Sa. To further confirm their interaction in vivo, 293T cells were co-transfected with an HA-RhoA expression plasmid together with either the FLAGtagged full-length, DA/ext-RBD mutant or the DB mutant and subjected to co-immunoprecipitation assays ( Figure 4f ). Consistent with the in vitro binding results, DA/ext-RBD could not be co-immunoprecipitated with RhoA. In contrast, binding of the full-length and DB mutant with RhoA were still intact. Similar results were also obtained for the binding of the endogenous RhoA to these mutants (data not shown). Thus, we have determined that the region consisting of amino acid 133-177 of the BCH domain indeed harbors a novel RhoA-binding region in BNIP-Sa. Presence of a cryptic GAP-binding motif that overlaps with minimal Rho-binding region in the BCH domain of BNIP-Sa Our previous reports had shown that both BNIP-2 and BNIP-Sa could bind p50RhoGAP via their respective BCH domains (Low et al., 2000a; Zhou et al., 2002) . In this regard, we proceeded to identify the binding motif for p50RhoGAP within the BNIP-Sa BCH domain by first subjecting the above two mutants (DA/ext-RBD and DB) and the wild-type BNIP-Sa to co-immunoprecipitation studies in vivo. We initially suspected that the region B that harbors the homophilic-interacting motif at residues 215-221 (Zhou et al., 2002) could well serve as the heterophilic-binding region for p50RhoGAP. Surprisingly, our results show that the region A/ext-RBD but not the region B was necessary for mediating the BNIP-Sa and p50RhoGAP interaction in vivo ( Figure 5a ). This unexpected result immediately raised the question whether BNIP-Sa targets RhoA and p50RhoGAP via the entire region A/ext-RBD, or through adjacent motifs within the designated ext-RBD. Alternatively, being a cognate substrate of p50RhoGAP, RhoA could be indirectly bridged to BNIP-Sa via p50RhoGAP. Likewise, p50RhoGAP binding could possibly be linked to RhoA that binds directly to the ext-RBD of BNIP-Sa. To shed light on these various possibilities, we further subdivided the region A/ext-RBD into two smaller parts and prepared two corresponding deletion mutants (DA1 and DA2/ RBD) so as to delineate further the exact binding regions (Figure 5b ). To serve as an additional negative control for binding specificity, DC mutant with other region of BCH being deleted was also prepared. To minimize the likelihood that various mutants would impact on the secondary and tertiary structure of BNIP-Sa that could lead to erroneous binding data, we employed bioinformatics tool (NPS@; http:// www.npsa-pbil.ibcp.fr) for the optimal predictions of the secondary structures where such deletions could be best carried out (data not shown). All mutants were thus generated and tested for their expression and solubility prior to use for subsequent co-immunoprecipitation assays. As shown in Figure 5c , p50RhoGAP could bind to all mutants except the two mutants lacking the A1 region (i.e. DA1 and DA). This result reveals that the A1 region acts as the specific p50RhoGAP-binding motif (GBM) for BNIP-Sa. We therefore named the A1 region as GBM. In contrast, DA1/GBM, DA2/RBD and DA mutants could not precipitate the overexpressed HARhoA, suggesting that the whole region A is already the minimal region necessary for targeting RhoA (Figure 5d ). Knowing that BNIP-Sa targets the BCH domaincontaining GAP via the A1/GBM, we were interested to know if this region is reiterated in other p50RhoGAP interaction proteins. Till now, beside the BNIP-2 family members, that interact with their BCH domains, RhoA is the only in vivo cognate substrate reported to interact with p50RhoGAP, and it does so by employing its Switch I region (Dvorsky and Ahmadian, 2004) . We therefore aligned the sequences of RhoA that encompasses the Switch I region (and its proximal flanking sequences) with the GBM of BNIP-Sa. Intriguingly, our ClustalW alignment reveals that this GBM region does share considerable degree of homology with part of the Switch I region of RhoA and its preceding alpha helices (amino acids 22-36) ( Figure 6a ).
We had attempted by even smaller deletions and subtle point mutations to further dissect the GBM of BNIP-Sa so as to distinguish it from the RhoA-binding motif. However, any mutants carrying deletion within the GBM failed to bind p50RhoGAP, and it also led to loss of binding to RhoA (data not shown). These cumulative results indicate that there is a cryptic GAPbinding motif that overlaps with the minimal RhoAbinding region in the BCH domain of BNIP-Sa.
With our current observations that the BCH domain of BNIP-Sa targets both RhoA and p50RhoGAP, we questioned whether the cellular effect of BNIP-Sa depends on its binding ability to either RhoA or p50RhoGAP, or both. However, since the mutant DA1/GBM failed to interact with both p50RhoGAP Figure 4 Identifying critical RhoA-binding region within the BCH domain of BNIP-Sa. (a) The full-length BNIP-Sa (FL), Nterminus that lacks the BCH domain (N) or C-terminus that harbors the BCH (CBCH) were generated as FLAG-tagged expression constructs as indicated. Cells were co-transfected with FLAG-tagged expression vectors for the full-length BNIP-Sa (FL), N or CBCH fragments together with HA-tagged RhoA. Lysates were subjected to immunoprecipation (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE and probed with anti-HA to reveal the binding of RhoA. Wcl, whole cell lysates. (b) An equal amount of lysates from 293T cells transfected with FLAG-BNIP-Sa CBCH was used in a pulldown (PD) experiment by incubating with equal amounts of GST-RhoA preloaded with GDP, GTPgS (indicated as GTP), or neither, as described under 'Materials and methods.' The bound protein was separated on SDS-PAGE, blotted, and probed with FLAG antibody. (c) 293T cells were transfected with expression vectors for HA-RhoA as either the wild type, G14V mutant or T19N mutant. Lysates were used in precipitation experiments using GST recombinants of BNIP-Sa and the associated proteins were separated on SDS-PAGE and probed with anti-HA. (d) Various expression constructs of BNIP-Sa were tagged with FLAG epitope as indicated: WT (the wild type), DA/ 'ext-RBD' (lacking amino acids 133-177, extending the putative RBD predicted from the sequence alignment as depicted in Figure 6a later) or DB (lacking amino acids 178-229, including a homophilic binding motif identified previously; Zhou et al., 2002) . (e) Nucleotide-free GST-RhoA or GST-BNIP-Sa (as control) recombinants were used to 'pulldown' (PD) cell lysates expressing the FLAG-tagged BNIP-Sa constructs. The associated proteins were separated on SDS-PAGE, blotted, and probed with anti-FLAG (upper panel). Blots were stripped and stained with amido black to reveal loading of the GST recombinants (bottom panel). (f) Cells were co-transfected with expression vectors for HA-RhoA and wild-type FLAG-BNIP-Sa or the deletion mutants. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE, blotted and probed with HA antibody. Expression of FLAG-tagged BNIP-Sa and HA-tagged RhoA were verified by Western blot analyses of the whole cell lysates (wcl) using anti-FLAG (first panel) and anti-HA (second panel), respectively. Equal loading of IP beads were verified by anti-FLAG (third panel), and the bound RhoA was detected by anti-HA (bottom panel). and RhoA, the exact role of BNIP-Sa binding to p50RhoGAP or RhoA could not be distinguishable using such mutant. Instead, we adopted the mutant DA2/RBD that failed to interact with RhoA to examine the requirement of RhoA binding in eliciting the cellular effect of BNIP-Sa. FLAG-tagged fusion proteins for the wild type and mutant DA2/RBD were expressed in MCF-7 cells and their effects on BNIP-Sa-induced apoptosis were monitored by immunofluorescence, with particular reference to the cell rounding effects. As a negative control and to show the specificity in conferring cellular effects, another deletion mutant of a polybasic region that is not involved in the binding of RhoA or p50RhoGAP (D201-205) was used. Figure 5e shows that cells expressing mutant DA2/RBD completely failed to elicit any cell rounding whereas those expressing the wild type and the control mutant continued to cause drastic cell rounding and cell death. Similar results were also obtained when the GFP-fusions of the wild type and mutants were performed under direct fluorescence microscopy and stained with Hoechst dye for nuclei integrity (data not shown). This result demonstrates that the binding of BNIP-Sa to RhoA is a key determinant for cell rounding and subsequent apoptosis.
BNIP-Sa disrupts the interaction between p50RhoGAP
and RhoA and helps restore RhoA activation We next explored the possible molecular basis underlying the BNIP-Sa-induced cellular effect. In light of the cryptic RhoGAP-binding motif that is present along with the RhoA-binding region, a 'competition' model could be envisaged whereby a trimeric complex could not be formed concomitantly. Here we hypothesize that the binding of BNIP-Sa to RhoA could exclude p50RhoGAP from binding to the site, and vice versa. Consequently, BNIP-Sa could disrupt the p50Rho-GAP-RhoA interaction and modulate cytoskeleton rearrangements. In this case, separate pools of BNIPSa could exist to target either p50RhoGAP or RhoA. This would then allow displacing p50RhoGAP from its physiological target and potentially augment RhoA activation.
To test this model, we first checked if BNIP-Sa could interact with both p50RhoGAP and RhoA at the same time. 293T cells were co-transfected with FLAG-BNIP-Sa and HA-tagged RhoA or p50RhoGAP, either together or separately. Lysates were subsequently precipitated with M2 anti-FLAG beads followed by Western blotting with anti-HA. Figure 6b demonstrates that BNIP-Sa showed significant reduction in binding to RhoA in the presence of p50RhoGAP. A similar observation was made when BPGAP1, a close homolog of p50RhoGAP was used in a parallel experiment. These results exclude the presence of BNIP-Sa-RhoGAP-RhoA trimeric complex. Next, we tested the binding between p50RhoGAP and RhoA in the presence or absence of BNIP-Sa. 293T cells were co-transfected with FLAG-tagged p50RhoGAP and HA-RhoA with or without HA-BNIP-Sa followed by immunoprecipitation assays. As a negative control, we carried out another binding assay by replacing HA-RhoA with HA-Rac1. Figure 6c shows that BNIP-Sa significantly affected the interaction between p50RhoGAP and RhoA. This is consistent with the requirement of an active RhoA pathway in mediating cell rounding elicited by BNIP-Sa. These results show that BNIP-Sa could disrupt the RhoA-p50RhoGAP complex and possibly release and activate RhoA for triggering apoptotic events.
To further confirm the above hypothesis, we next examined how the GAP activity of the p50RhoGAP could be regulated by BNIP-Sa in vivo. Cells were cotransfected with HA-tagged RhoA, together with either the HA-p50RhoGAP, HA-BNIP-Sa or both. The amount of active RhoA in vivo was then determined by the magnitude of its preferred binding to the RBD of the Rho effector, rhotekin, as described under 'Materials and methods.' Figure 6d shows that in vivo, the activity of RhoA was reduced by overexpressed p50RhoGAP whereas coexpression of BNIP-Sa helped restore the RhoA activity.
All these results indicate that BNIP-Sa could displace p50RhoGAP's inhibition on RhoA, thus bringing about RhoA activation through its interaction with this GTPase. Such interaction is necessary for its cell rounding and apoptotic effects. Next, we examined the possible mechanisms on how p50RhoGAP itself could be sequestered upon binding to BNIP-Sa. The presence of the RhoGAP-binding motif (GBM) that is within the BCH domain of BNIP-Sa and resembles part of the Switch I region of RhoA (amino acids 22-36) (Figure 6a ) suggest two possibilities: (1) this motif could be directly involved in mediating the heterophilic interaction with the corresponding BCH domain of the p50RhoGAP as we previously described (Zhou et al., 2002) ; (2) this motif could function in a manner similar to the Switch I region of RhoA and is involved in binding to the effector or regulator -in this case, the GAP domain. To prove this, the full-length p50RhoGAP, the N-terminus part that carries the BCH domain (NBCH) or the C-terminus part that harbors the proline-rich region plus the GAP domain (PGAP) was coexpressed with HA-BNIP-Sa. Immunoprecipitation of these fragments revealed that indeed only the NBCH fragment could mediate the interaction between p50RhoGAP and BNIP-Sa (Figure 6e ). Taken together, we postulate that BNIP-Sa could utilize its BCH domain to regulate cell rounding by targeting inactive RhoA (since it prefers GDP-bound form) after displacing p50RhoGAP by forming a heterophilic complex via the latter's BCH domain.
BNIP-Sa suppress p50RhoGAP effects on cell protrusions while promoting cell rounding through its interaction with RhoA Next, we set out to identify any physiological significance of the effect of BNIP-Sa on the RhoA-p50Rho-GAP interaction, by investigating its role(s) in modulating the biological responses elicited by p50RhoGAP. Since BNIP-Sa could function as a key regulator for p50RhoGAP-RhoA interaction, we next examined if BNIP-Sa could negatively regulate the effects of p50RhoGAP on cell dynamics. Our group previously reported that the newly identified p50RhoGAP homolog, BPGAP1, could induce pseudopodia via the inactivation of RhoA in vivo (Shang et al., 2003) . We thus postulated that p50RhoGAP could induce similar cell dynamics, and serve as a marker for directly testing the role of BNIP-Sa on the RhoA-p50RhoGAP pathway. MCF-7 cells were transfected with expression plasmids of either GFP-tagged p50RhoGAP or vector control. Confocal fluorescence microscopic studies showed that while control cells with the GFP vector alone exhibited a regular cuboidal shape, the expression of p50RhoGAP could induce cell protrusions which were abolished by coexpression of the constitutive active mutant of RhoA, G14V (Figure 7a ). This observation showed that p50RhoGAP could induce cell protrusions via inactivating RhoA and led to our hypothesis that such cellular effect could be abolished by BNIP-Sa. We tested this hypothesis by coexpression of the GFPtagged p50RhoGAP with either the wild-type BNIP-Sa, two deletion constructs (DA1/GBM or DA2/'RBD'), or a control mutant not involved in RhoA or RhoGAP binding (D201-205). It can be seen in Figure 7b that the p50RhoGAP-induced pseudopodia formation could be effectively blocked by the wild-type and control mutant which still retained the ability to interact with p50Rho-GAP and RhoA, but not with the binding-deficient DA1/GBM or DA2/'RBD' mutants. Two conclusions can be made from the above data: (1) BNIP-Sa binding to p50RhoGAP can sequester the RhoGAP, via its GBM motif, and seemingly prevent it from inactivating RhoA, and (2) disrupting RhoGAP binding to RhoA itself is not sufficient to lead to cell rounding, but this effect also requires BNIP-Sa and RhoA interaction, as indicated by the requirement for A2/'RBD' region. Taken together, by ascertaining the key binding motifs within the BCH domain of BNIP-Sa and linking these to cell morphological studies, we have revealed in BNIP-Sa a previously unanticipated cryptic binding motif for p50RhoGAP that also overlaps with the RhoA-binding region. Therefore, via unique binding motifs within its BCH domain, BNIP-Sa could interact and activate RhoA primarily by preventing its inhibition by p50RhoGAP. Concomitantly, the formation of BNIP-Sa-p50RhoGAP via their homologous BCH domains could provide an additional means to help ensure low level of p50RhoGAP-RhoA interaction (see model in Figure 8 ). This concerted mechanism could allow effective propagation of the active RhoA-signaling pathway necessary for cell rounding and apoptosis.
Discussion
Our results demonstrate that an active RhoA pathway is critical for BNIP-Sa-induced cell rounding as part of its proapoptotic role in the cells. Two distinct regions were identified within the BCH domain of BNIP-Sa that are crucial for such an effect: (1) a region (148-177) that is similar to the REM/class I type Rho-binding motif, and (2) the adjacent RhoGAP binding motif (GBM; residues 133-147) which is similar to part of the Switch I region (and the preceding alpha-helices) of RhoA commonly used in binding its effectors. Functionally, both the RBD and GBM are necessary for RhoA binding whereas only the GBM is required for p50RhoGAP Figure 6 BNIP-Sa displaces p50RhoGAP inhibition on RhoA. (a) A schematic model showing different motifs within the BNIP-Sa BCH domain that are involved in mediating its interaction with RhoA (via Region A that extends the putative RBD, i.e. ext-RBD that includes also Region A1) and p50RhoGAP (via Region A1 or the GAP-binding motif, GBM). Region A1 also shows discrete homology to part of RhoA Switch I region and the sequence immediately before that. Sequence alignment of the BNIP-Sa BCH domain with different Rho-binding domains (RBD) of Rhophilin-1 (NP_443156), Rhophilin-2 (AAK58588), PRK1/PKN (NP_002732), PRK2 (NP_006247), Rhotekin (AAH17727) and MEKK1 (P53349) reveals a putative RBD at region 148-177 of BNIP-Sa. Protein sequences were aligned using the ClustalW and displayed by BOXSHADE. Identical amino acids are shown in black, and similar residues are highlighted in gray. (b) In vivo binding of BNIP-Sa and RhoA in the presence or absence of RhoGAP. Cells were co-transfected with expression vectors as indicated. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE, blotted and probed with HA antibody. Expression of FLAG-tagged BNIP-Sa and HA-tagged proteins (RhoGAP or Rho GTPases) were verified by Western blot analyses of the whole cell lysates (wcl) using anti-FLAG (first panel) and anti-HA (second and third panels), respectively. Equal loading of IP beads were verified by anti-FLAG (fourth panel), and the HA-tagged proteins was revealed by anti-HA (fifth and bottom panels). (c) In vivo binding of p50RhoGAP and RhoA in the presence or absence of BNIP-Sa. Cells were co-transfected with expression vectors as indicated. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE, blotted and probed with HA antibody. Expression of FLAG-tagged p50RhoGAP and HA-tagged proteins (BNIP-Sa or Rho GTPases) were verified by Western blot analyses of the whole cell lysates (wcl) using anti-FLAG (first panel) and anti-HA (second and third panels), respectively. Equal loading of IP beads were verified by anti-FLAG (fourth panel), and the HA-tagged proteins was revealed by anti-HA (fifth and bottom panels). (d) In vivo GTPase assays. Cells were transfected with HA-tagged wild-type RhoA in the presence of either HA-tagged p50RhoGAP or BNIP-Sa or both. Cell were lysed and incubated with GST fusion of the Rho-binding domain of rhotekin immobilized on beads, in order to assess the roles BNIP-Sa in regulating RhoA and p50RhoGAP activity as described under 'Materials and methods.' Bound GTPases were resolved on SDS-PAGE and detected by immunoblotting with HA-antibody (second panel). Expression of BNIP-Sa, p50RhoGAP and RhoA were verified by anti-HA (top panel). One nonspecific band appears slightly below the position of HA-BNIP-Sa. Equal loading of GST fusion proteins is shown in the bottom panel. (e) Dissecting the domain of p50RhoGAP that binds BNIP-Sa. The full-length p50RhoGAP (FL), C-terminus (PGAP) that harbors the proline-rich region (PRR) and GAP domain or N-terminus (NBCH) that harbors the BCH, were all generated as FLAG-tagged expression constructs as indicated. Cells were co-transfected with FLAG-tagged expression vectors for the full-length p50RhoGAP (FL), PGAP or NBCH fragments together with HA-tagged BNIP-Sa. Lysates were subjected to immunoprecipation (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE and probed with anti-HA to reveal the binding of BNIP-Sa. Wcl, whole cell lysates.
interaction. Consequently, the GBM creates a platform for competition between RhoA and p50RhoGAP, its cognate inactivator. Working in concert, overexpressed BNIP-Sa could prevent p50RhoGAP from inactivating RhoA while at the same time, based on the competitive nature of binding, different pools of BNIP-Sa function to facilitate RhoA activation.
Although the hallmarks of an apoptotic cell include dynamic morphological changes such as cell shrinkage, loss of adherence and cell rounding (in adherent cells), it has recently become clearer that the integrity of the cytoskeletal network could itself form an important element in the active regulation of apoptosis, rather than a passive consequence of apoptosis. Early studies BNIP-Sa suppresses p50RhoGAP effects on cell protrusions while promoting cell rounding through its interaction with RhoA. (a) MCF-7 cells were transfected for 20 h with expression plasmids for either GFP, FLAG-tagged BNIP-Sa, or GFP-tagged p50RhoGAP alone or together with HA-tagged RhoA G14V. Cells were then fixed, permeabilized, and incubated with HA polyclonal antibody, followed by Texas red dye-conjugated goat anti-rabbit IgG (red) or FLAG monoclonal antibody followed by Texas red dyeconjugated rabbit anti-mouse IgG (red) for indirect immunofluorescence detection. GFP fusions were directly observed under green fluorescence. (b) MCF-7 cells were co-transfected for 20 h with expression plasmids for GFP-tagged p50RhoGAP with FLAG-tagged BNIP-Sa or the deletion mutants. Cells were then fixed, permeabilized, and incubated with FLAG monoclonal antibody, followed by Texas red dye-conjugated rabbit anti-mouse IgG (red) for the fluorescence detection. Bar, 50 mm.
indicated that at the cellular and biochemical level, activation of RhoA leads to stress fiber formation, cell rounding and neurite retraction (Hall, 1998) . More recent studies have revealed the participation of RhoAsignaling pathways in mediating apoptosis (Aznar and Lacal, 2001; Coleman and Olson, 2002) , either through its activation or inactivation. For examples, inactivation of RhoA has been reported to cause apoptosis in epithelial cells (Fiorentini et al., 1998a, b) , fibroblasts (Bobak et al., 1997) and differentiating myoblasts (Reuveny et al., 2004) , while others demonstrated that RhoA activation instead lead to apoptosis in endothelial cells (Bayless and Davis, 2004) , neurons and glial cells (Dubreuil et al., 2003) , and fibroblast cells (Subauste et al., 2000; Ueda et al., 2004) . Similarly, there are studies showing that both restoration (Zhou et al., 2004) and knockout (Wang et al., 2005a, b) of RhoGAP proteins could result in cell death. Taken together, these data demonstrates the importance of maintaining balanced RhoA activity in cell survival.
A number of proteins were identified as interaction partners of RhoA and the RhoA interaction regions of these proteins can be divided into two groups based on the homology of primary amino-acid sequences. Class 1, also named REM (Rho effector motif), includes the Rho-binding regions of PKN, rhotekin, rhophilin-1, rhophilin-2, PRK2 and MEKK1 while class 2/RKH (ROK-kinectin homology) contains Rho-kinase, p160 ROCK and other RhoA-interacting coiled-coil-containing proteins (Bishop and Hall, 2000) . Sequence alignment studies revealed that the Rho-binding motif of BNIP-Sa is similar to the class 1 binders. Interestingly, the region required for RhoA-binding includes not only the standard class 1 RBD motif, but also a GAP-binding region that shares similarity with the RhoA Switch I region. A similar scenario was observed in the M-RIP protein whose RBD overlaps with the region for interacting with Myosin Binding Subunit (MBS) (Surks et al., 2003) . In contrast to the model where the M-RIPbinding region brings MBS and RhoA into close proximity, our current studies present an opposing 'competition/sequestration' model. Recently, several proteins were reported to interact with either RhoA protein or its regulators indicating a similar sequestration mode of action. For example, p75 neurotrophin receptor could facilitate the release of prenylated RhoA from Rho-GDI by targeting Rho-GDI (Yamashita and Tohyama, 2003) . A similar observation was reported with the ERM (ezrin/radixin/moesin) protein, which could also function as a Rho-GDI displacement factor to induce activation of RhoA in Swiss 3T3 cells (Takahashi et al., 1997) . Interestingly, RhoA, but not its regulator, was found to be targeted by Etk which resulted in its dissociation from the RhoA-GDI complex (Kim et al., 2002) . Beside GDI, GAP protein could be an alternative target as shown in a study involving CdGAP whose GAP activity can be negatively regulated by interacting with intersectin via its proline-rich sequence (Jenna et al., 2002) . Similarly, a guanine nucleotide-exchange protein BIG1 was recently found to compete with RhoA for the binding to myosin IXb, thus resulting in the inhibition of the myosin IXb GAP activity (Saeki et al., 2005) . The study on p190GAP protein indicated that a different regulatory model was involved. The GTPase Rnd protein was reported to target p190GAP and this interaction increases the p190 GAP activity towards GTP-bound RhoA (Wennerberg et al., 2003) . In a different scenario, we have demonstrated here that BNIP-Sa interacted with p50RhoGAP and competed with them in binding to RhoA, in an apparently parallel manner to those seen with Rho-GDI and myosin IXb. Activated RhoA is critical in BNIP-Sainduced apoptosis and in addition BNIP-Sa could negatively regulate p50RhoGAP-mediated cellular effects. This data provides new insights in the mechanism by which Rho GTPases play a role in apoptosis. Indeed, the cell rounding and apoptotic effects exerted by BNIPSa is unique as it does not lead to activation of conventional caspases (Zhou et al., 2002) nor it involve the p53-signaling pathway as treatment with specific inhibitor to p53 (e.g. pififthrin) failed to block both cellular effects (Zhou and Low, unpublished data) . Although RhoA has been shown to positively or negatively regulate apoptosis, the intricacy of RhoAlinked cytoskeleton-based apoptotic signals is likely to depend on various intracellular thresholds (such as coupling to BNIP-Sa) as well as other external stimuli (such as substratum contacts). Taken together, these data demonstrates the importance of maintaining balanced RhoA activity in cell survival, and BNIP-Sa could be just one of the key regulators to control such balance during this event.
Our previous studies showed that BCH domains function by employing multiple binding motifs Figure 8 A mechanistic model for the effect of BNIP-Sa on cell rounding and apoptosis. BNIP-Sa-induced cell rounding and apoptosis could be blocked by a dominant-negative form of RhoA whereas the inactivation of RhoA is required for p50RhoGAP-mediated cell protrusions. BNIP-Sa binding to RhoA via its extended Rho-binding domain (ext-RBD) is essential and it plays a primary role in facilitating RhoA activation. This is achieved at least by forming a BNIP-Sa-RhoA complex that displaces p50RhoGAP from inhibiting RhoA (indicated as thick arrow). As an additional mechanism, BNIP-Sa could help ensure a low level of p50RhoGAP-RhoA by directly targeting and sequestering p50RhoGAP via its GAP-binding motif (GBM). However, this event alone is not sufficient to cause cell rounding (indicated as dotted arrow).
contained within the greater domain. For example, an arginine-finger patch in BNIP-2 is necessary for its GAP-like activity or the other distinct region for its homophilic/heterophilic interactions (Low et al., 2000a) . Likewise, a distinct region in BNIP-Sa BCH domain is also involved in conferring homophilic binding and this sequence is also required for its cell rounding and apoptotic effects (Zhou et al., 2002) . However, unlike the BNIP-2 counterpart where the same motif is employed for either homophilic or heterophilic interaction, the BNIP-Sa adopts a distinct GAP-binding motif to form a heterophilic complex with the BCH domain of p50RhoGAP. Currently, it is unclear whether the ability of BNIP-Sa to partake in homophilic interactions forms part of the overall mechanism for RhoA effects on cell rounding. In connection to the possible mechanism on how function of p50RhoGAP might be regulated by BNIP-Sa, we further verified that p50RhoGAP interacts with the BNIP-Sa's GBM via its homologous BCH domain, and not through its GAP domain. This is not too surprising given that BCH domains are involved in mediating homophilic or heterophilic interactions. What is intriguing is the nature of the GAP-binding motif that shares some homology to the Switch I region of Rho that would normally be involved in recognizing GAP. This result would implicate the possible adaptation of a common motif that had undergone changes to cater for diverse targets.
With such unique binding motifs within its BCH domain, BNIP-Sa could interact and activate RhoA directly while at the same time preventing RhoA inhibition by p50RhoGAP. This could be achieved either in the presence or absence of sequestration of p50RhoGAP by BNIP-Sa. However, without the BNIPSa mutant that only fails to bind p50RhoGAP but not RhoA, we could not confirm with certainty at this stage whether BNIP-Sa binding to p50RhoGAP and thus its sequestration (in addition to the absolute requirement for RhoA binding) was indeed necessary for its cellular effects. However, since RBD deletion that disrupts RhoA binding alone (but without affecting p50Rho-GAP) was already sufficient to attenuate BNIP-Sa effects, it is clear that RhoA binding to BNIP-Sa plays the primary role on cell rounding and apoptosis. However, in light of the strong competition from BNIP-Sa that inhibits p50RhoGAP binding to RhoA, we speculate that such sequestration via BNIP-Sap50RhoGAP could play a secondary role in helping to maintain a low level of RhoGAP-RhoA complex inside the cells. This would help ensure the propagation of an active RhoA signaling pathway.
Interestingly, a variant Cdc42-binding motif from the conventional Cdc42/Rac-Interacting Binding (CRIB) motif was recently identified within the BNIP-2 BCH domain that mediates cell protrusions and not cell rounding (Zhou et al., 2005) . Compared to the effects of BNIP-2 that causes cell protrusions via the Cdc42 pathway, our current results explain why these two similar proteins lead to distinct cellular effects, that is Cdc42 binding and activation requires the BCH domain of BNIP-2 while RhoA binding and activation requires binding to a distinct motif on the BCH domain of BNIP-Sa. It is of interest that such subtle sequence differences between BNIP-2 and BNIP-Sa can result in different physiological outcomes. In either case, it is noteworthy that the BCH domains exhibit greater binding affinity towards the dominant negative forms of Cdc42 (Low et al., 2000b) or RhoA (current report) as compared to their constitutive active counterparts when expressed in the cells. It remains to be seen how such activation of small GTPases can be attained at the molecular levels and whether other co-regulators could be brought to the vicinity of BNIP-2/Cdc42 or BNIPSa/RhoA complexes, respectively. All these data further highlight the emerging role of BCH domain as an important regulator of cell dynamics that are mediated at least by the various Rho GTPase family members and indicate that there is much to be elucidated on the role of their interactions in cellular physiology. This would add to our better understanding of the plasticity and specificity of this new class of protein domain in cell dynamics control.
Materials and methods
Cell culture and transfection
Human MCF-7 and 293T cells were grown in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (all from Hyclone), and maintained at 371C in a 5% CO 2 atmosphere. Cells at 90% confluence in 100-mm plates or six-well plates were transfected with 4 or 0.4 mg of indicated plasmids using Fugene cationic lipids according to the manufacturer's instructions (Roche).
Construction of expression plasmids
Full-length cDNA of BNIP-Sa was cloned into a hemagglutinin (HA)-tagged, GFP-and FLAG-tagged expression vector, pXJ40 (Dr E Manser, IMCB, Singapore) or into pGEX4T-1 vector for producing the GST recombinant protein as described previously (Zhou et al., 2002) . Deletion mutants of BNIP-Sa were generated by polymerase chain reaction using specific primers facilitated by restriction sites. For each construct, several clones were chosen and sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing kit (Applied Biosystem) to the entirety in both directions to confirm their identity. All plasmids were purified using Qiagen miniprep kit for use in transfection experiments. Escherichia coli strain DH5a was used as host for propagation of the clones.
Bioinformatics
The secondary structure of BNIP-Sa was predicted with the NPS@ (Network Protein Sequence @nalysis) consensus secondary structure prediction web server (http://www.npsapbil.ibcp.fr) that incorporated 10 secondary structure prediction methods: SOPM, DPM, DSC, GOR-IV, HNNC, PHD, PREDATOR, SIMPA96, SOPM and Sec.Cons (Combet et al., 2000) . To identify any putative RBD/motif (RBD) within the BNIP-Sa BCH domain, the sequence of BNIP-Sa BCH domain (amino acids 133-275) was used for alignment with several known RBD domains in the NCBI databases (http:// www.ncbi.nlm.nih.gov) using the ClustalW (http://www2. ebi.ac.uk/clustalw/). Outputs of the multiple sequence align-ment were displayed with BOXSHADE 3.21 (http:// www.ch.embnet.org).
Precipitation/'pulldown'studies and Western blot analyses Control cells or cells transfected with expression plasmids were lysed in 1 ml of lysis buffer (50 mM HEPES, pH 7.4, 150 mM sodium chloride, 1.5 mM magnesium chloride, 5 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, a cocktail of protease inhibitors (Roche Molecular Biochemicals) and 5 mM sodium orthovanadate). The lysates were directly analysed either as whole-cell lysates (25 mg) or aliquots (500 mg) were used in affinity precipitation/'pulldown' experiments with various GST fusion proteins (5 mg) as previously described (Low et al., 1999) . Samples were run in SDS/PAGE gels and analysed by Western blotting with anti-HA (Zymed) or anti-FLAG (Sigma). Loading of GSTs were assessed by staining the blots with amido black.
Immunoprecipitation studies 293T cells were transfected with expression vectors for FLAGtagged proteins alone or together with HA-tagged constructs. Lysates were immunoprecipitated (IP) with anti-FLAG M2 beads (Sigma) and the associated proteins separated on SDS-PAGE, and probed with anti-HA (for cotransfection experiments), or with anti-Cdc42 (Santa Cruz), anti-Rac1 (Upstate Biotechnology) or anti-RhoA (Upstate Biotechnology) for detection of the endogenous Rho GTPases.
Immunofluorescence and direct fluorescence studies Cells were seeded on coverslips in a six-well plate and transfected with various expression constructs for 16 h and then stained for immunofluorescence detection using confocal fluorescence microscopy or directly visualized for cells expressing GFP-tagged proteins as previously described (Lim et al., 2000) . FLAG-tagged proteins were detected with monoclonal anti-FLAG followed by Texas Red s or FITC s dye-conjugated goat anti-mouse IgG (Jackson ImmunoResearch). Filamentous actin was detected by rhodamine-phalloidin (Molecular Probes) and microtubule was detected by antitubulin (Sigma) followed by Texas Red s dye-conjugated goat anti-mouse IgG (Jackson ImmunoResearch).
Apoptosis assays by nuclear staining To stain for chromatin integrity, cells were transfected with GFP vector or GFP-BNIP-Sa for the times indicated and then incubated for 10 min with 10 mg/ml of Hoechst dye (Sigma), washed with phosphate-buffered saline, and directly examined by microscopy. Cells undergoing apoptosis exhibited an irregular pattern of chromatin staining with Hoechst dye compared with homogenous staining in live cells (Spector et al., 1998) .
RhoA activity assays
Assays for the active (GTP-bound) form of RhoA was performed as described previously (Zhou et al., 2005) . Briefly, cells were co-transfected for 24 h with HA-tagged RhoA in the absence or presence of HA-tagged p50RhoGAP or/and HAtagged BNIP-Sa. Cells were then lysed and subjected to pulldown assays with GST fusion of the RBD of rhotekin which would bind and detect active RhoA in vivo (plasmid kindly provided by Dr Simone Schoenwaelder; Monash University, Australia). Bound RhoA were separated on SDS-PAGE gels, and subjected to Western blot analysis with the HA antibody.
